Drug Use Investigation for TYKERB Tablet (All Case Investigation)

Novartis

Status: Completed

Conditions: Cancer

Treatments: Drug: Lapatinib

Study type: Observational

Funder types: Industry

Identifiers

NCT01332396

113092

Details and patient eligibility

About

Data on the safety and efficacy of TYKERB shall be collected from the patients in order to grasp the actual conditions of post-marketing use and assess background information on the patients.

Enrollment: 4,054 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with HER2 overexpressing inoperable or recurrent breast cancer

Exclusion criteria

• Patients with hypersensitivity to lapatinib or any components
• Pregnant women and women suspected of being pregnant

Trial design

4,054 participants in 1 patient group

Patients prescribed TYKERB

Description:

Patients with HER2 overexpressing inoperable or recurrent breast cancer

Treatment:

Drug: Lapatinib